dovitinib   Click here for help

GtoPdb Ligand ID: 5962

Synonyms: Chir 258 | CHIR-258 | TKI 258 | TKI-258
Compound class: Synthetic organic
Comment: Dovitinib is a multi-targeted receptor tyrosine kinase (RTK) inhibitor, with modest selectivity for Class III RTKs (IC50s 1-2nM), with IC50s for Class IV and V RTKs in the 8-13nM range. Please note that ChEMBL represents this compound as a tautomer of our structure.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 5
Hydrogen bond donors 3
Rotatable bonds 1
Topological polar surface area 61.93
Molecular weight 392.18
XLogP 3.52
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES CN1CCN(CC1)c1ccc2c(c1)[nH]c(=C1C(=O)N=c3c(=C1N)c(F)ccc3)[nH]2
Isomeric SMILES CN1CCN(CC1)c1ccc2c(c1)[nH]/c(=C/1\C(=O)N=c3c(=C1N)c(F)ccc3)/[nH]2
InChI InChI=1S/C21H21FN6O/c1-27-7-9-28(10-8-27)12-5-6-14-16(11-12)25-20(24-14)18-19(23)17-13(22)3-2-4-15(17)26-21(18)29/h2-6,11,24-25H,7-10,23H2,1H3/b20-18-
No information available.
Summary of Clinical Use Click here for help
Dovitinib progressed to Phase 3 evaluation in patients with advanced solid tumours. Click here to link to's currently registered drug trials involving this compound. Most of these studies are marked as 'terminated' (a few due to drug toxicity concerns), 'withdrawn' or 'completed'.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
This compound inhibits key receptor tyrosine kinases that are implicated in tumor vasculature formation and maintenance, and which underlie tumor progression and metastasis.